Impact of a drug utilization review program on high‐risk use of prescription controlled substances

Abstract

Retrospective drug utilization review programs may reduce controlled substance scores and claims among individuals with patterns suggesting high-risk utilization.

The effect of an abuse‐deterrent opioid formulation (OxyContin) on opioid abuse‐related outcomes in the postmarketing setting

“…During the observation period, there were national and regional programs whose aim was to decrease prescription opioid abuse, e.g., prescription drug monitoring program inception or increased use, Florida's “pill mill” legislation, classwide ER Opioid REMS, drug take‐back programs, increased law enforcement efforts, and drug utilization reviews by managed care organizations . These programs were general opioid interventions that were not targeted specifically at OC.…”

Effects of a prior authorization policy for extended‐release/long‐acting opioids on utilization and outcomes in a state Medicaid program

“…To assist clinicians and policy makers, federal, state and local authorities have developed and disseminated evidence‐based opioid prescribing guidelines . In addition, health‐care systems and payers have re‐aligned policy and payment mechanisms to encourage safer opioid prescribing .…”

Trends in opioid prescribing and co-prescribing of sedative hypnotics for acute and chronic musculoskeletal pain: 2001-2010

“…Prescription‐drug monitoring programs, now approved in 49 states, can be leveraged to identify patients receiving sedative hypnotics or additional opioids from other providers . Providing prescribers with reports derived from pharmacy claims for patients with high‐risk opioid prescribing patterns, such as from multiple providers and pharmacies, has been shown to reduce risky prescribing …”

“…29 Providing prescribers with reports derived from pharmacy claims for patients with high-risk opioid prescribing patterns, such as from multiple providers and pharmacies, has been shown to reduce risky prescribing. 30,31 We identified an increase in opioid prescribing for acute and chronic musculoskeletal pain visits from 2001 to 2010; however, opioid prescribing at chronic pain visits plateaued from 2006 to 2010. Coprescribing of opioids and sedative hypnotics is common and may represent a target for interventions to improve the safety of opioid prescribing.…”